251 related articles for article (PubMed ID: 27266954)
1. Costs and spillover effects of private insurers' coverage of hepatitis C treatment.
Moreno GA; Mulligan K; Huber C; Linthicum MT; Dreyfus D; Juday T; Marx SE; Gonzalez YS; Brookmeyer R; Lakdawalla DN
Am J Manag Care; 2016 May; 22(6 Spec No.):SP236-44. PubMed ID: 27266954
[TBL] [Abstract][Full Text] [Related]
2. Value of expanding HCV screening and treatment policies in the United States.
Linthicum MT; Gonzalez YS; Mulligan K; Moreno GA; Dreyfus D; Juday T; Marx SE; Lakdawalla DN; Edlin BR; Brookmeyer R
Am J Manag Care; 2016 May; 22(6 Spec No.):SP227-35. PubMed ID: 27266953
[TBL] [Abstract][Full Text] [Related]
3. The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.
Rein DB; Borton J; Liffmann DK; Wittenborn JS
Hepatology; 2016 Apr; 63(4):1135-44. PubMed ID: 26707033
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
[TBL] [Abstract][Full Text] [Related]
7. Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations.
Moreno GA; Wang A; Sánchez González Y; Díaz Espinosa O; Vania DK; Edlin BR; Brookmeyer R
Value Health; 2017 Jun; 20(6):736-744. PubMed ID: 28577690
[TBL] [Abstract][Full Text] [Related]
8. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
[TBL] [Abstract][Full Text] [Related]
9. The role of insurance providers in supporting treatment and management of hepatitis C patients.
Behzadifar M; Gorji HA; Rezapour A; Behzadifar M; Bragazzi NL
BMC Health Serv Res; 2019 Jan; 19(1):25. PubMed ID: 30630488
[TBL] [Abstract][Full Text] [Related]
10. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of total state coverage for hepatitis C medications.
Padula WV; Levin JS; Lee J; Anderson GF
Am J Manag Care; 2021 May; 27(5):e171-e177. PubMed ID: 34002969
[TBL] [Abstract][Full Text] [Related]
12. Medicare essential: an option to promote better care and curb spending growth.
Davis K; Schoen C; Guterman S
Health Aff (Millwood); 2013 May; 32(5):900-9. PubMed ID: 23650323
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
Rattay T; Dumont IP; Heinzow HS; Hutton DW
Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
[TBL] [Abstract][Full Text] [Related]
15. The wider public health value of HCV treatment accrued by liver transplant recipients.
Jena AB; Stevens W; Gonzalez YS; Marx SE; Juday T; Lakdawalla DN; Philipson TJ
Am J Manag Care; 2016 May; 22(6 Spec No.):SP212-9. PubMed ID: 27266951
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
17. Treating Medicaid patients with hepatitis C: clinical and economic impact.
Younossi Z; Gordon SC; Ahmed A; Dieterich D; Saab S; Beckerman R
Am J Manag Care; 2017 Feb; 23(2):107-112. PubMed ID: 28245654
[TBL] [Abstract][Full Text] [Related]
18. Association of National Expansion of Insurance Coverage of Medically Tailored Meals With Estimated Hospitalizations and Health Care Expenditures in the US.
Hager K; Cudhea FP; Wong JB; Berkowitz SA; Downer S; Lauren BN; Mozaffarian D
JAMA Netw Open; 2022 Oct; 5(10):e2236898. PubMed ID: 36251292
[TBL] [Abstract][Full Text] [Related]
19. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
McEwan P; Ward T; Yuan Y; Kim R; L'italien G
Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
